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Available online 4 March 2008It is known that protein kinase C (PKC) signal transduction is enhanced in a diabetic state, and that PKC
activator phorbol esters increase the gene expression of MDR1 in human tumor cells. To clarify the expression
of the liver transporters under diabetic conditions and the roles of PKCα and the transcription factor NF-κB, we
investigated the expression levels of Mdr1a, Mdr1b, Mdr2, Mrp2, Bcrp, Bsep, Oct1, Oat2, and Oat3
transporters, PKCα, IκB, and NF-κB in the liver of rats with STZ-induced hyperglycemia. A selective increase in
the gene expression of Mdr1b was detected by RT-PCR. Western blotting with C219 antibody revealed an
increase in P-glycoprotein. Although the mRNA level of PKCα was not affected, translocation of PKCα to the
microsomal fraction was detected. NF-κB p65, IκBα and IκBβ mRNA levels were increased as was the level of
nuclear NF-κB p65. From these ﬁndings, it was suggested that STZ-induced hyperglycemia caused the
upregulation of Mdr1b P-gp expression through the activation of PKCα and NF-κB.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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Hepatocytes express various transporter proteins that take up and
export xenobiotics and bile components. These transporters include the
solute carrier family protein organic cation transporter 1 (Oct1), organic
anion transporter (Oat) 2, and Oat3, and ATP-binding cassette (ABC)
transporters, Mdr1a (Abcb1a), Mdr1b (Abcb1b), Mdr2 (Abcb4), Mrp2
(Abcc2), Bcrp (Abcg2), and Bsep (Abcb11). Mdr1a and Mdr1b are
homologues of human MDR1 P-glycoprotein (P-gp) which transports
xenobiotics such as doxorubicin and cyclosporin A [1]. The Mdr2 P-gp, a
homologueofMDR3 in humans, transports phosphatidylcholine into bile.
Mrp2 is a transporter of organic anions such as bilirubin glucuronides.
Bcrp is known as a transporter of methotrexate, and Bsep is an export
pump of bile acids.
Several reports have indicated that the expression of transporters
was affected by various chemical substances and pathophysiological
conditions [2–5]. In rats with streptozotocin (STZ)-induced diabetes,
van Waarde et al. [6] showed that the Mdr2 gene expression and theakusawa).
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l rights reserved.protein level were increased in the liver and that the secretion of
biliary phospholipids was enhanced. HumanMDR1 gene expression is
well known to be enhanced by various stimulants including antitumor
drugs [7] and protein kinase C activator phorbol esters [8,9]. As for two
rat Mdr1 genes, it has been reported that the Mdr1a gene lacked any
response to STZ while the Mdr1b gene showed a massive increase in
expression in both the liver and kidney after STZ treatment [10]. The
different responses of these two Mdr1 genes have also been seen in
LPS-induced endotoxemic rat liver [11] and in doxorubicin-treated rat
astrocytes [12], in which only the Mdr1b gene was upregulated. Thus,
the Mdr1b gene prefers to respond to external stimulations as in the
case of the human MDR1 gene, although whether the P-gp level is
affected under diabetic conditions has remained unclear.
It is widely recognized that the PKC signal transduction system is
enhanced in the diabetic state [13]. PKC expression is persistently
upregulated and this is recognized as an initial event leading to insulin
resistance, cardiac disease, and nephropathy in diabetes [14]. It is also
indicated that the activation of PKC is involved in the hyperglycemia-
induced sustained activation of the transcription factor NF-κB [15,16].
PKC consists of a family of at least eleven isoforms, which are
categorized into the classic (α, β1, β2, γ), the novel (δ, ε, η, θ, µ), and the
typical (ζ, ι) [17,18]. Among these isoforms, PKCα activated in kidney
cells, is indicated to mediate NF-κB's activation [19].
In the present study, to clarify the changes in the expression of the
liver transporters underdiabetic conditions and the role of PKC isoforms,
Table 1
Primer sets for PCR
Forward (5′–3′) Reverse (5′–3′) Annealing temperature Product size Ref
Mdr1a GGGCCACATGATCAAGACGG AGCGTCATTGGCAAGCCTGG 65 447 [2]
Mdr1b ACAGAAACAGAGGATCGC AGAGGCACCAGTGTCACT 55 352 [15]
Mdr2 ACAGAAACAGAGGATCGCCA ATGCGTGCTTTCCAGCCA 55 386 [15]
Bsep TGCTTATGGGAGGCGTAT GGGCTGACAGCAAGAATC 55 565 [16]
Mrp2 GGCTGAGTGCTTGGAC CTTCTGACGTCATCCTCAC 55 789 [17]
Bcrp CAATGGGATCATGAAACCTG GAGGCTGGTGAATGGAGAA 60 536 [18]
Oct1 GATCTTTATCCCGCATGAGC TTCTGGGAATCCTCCAAGTG 60 478 [19]
Oat2 CGCTCAGAATTCTCCTCCAC ACATCCAGCCACTCCAACTC 60 311 [20]
Oat3 TGAGAAGTGTCTCCGCTTCG CTGTAGCCAGCGCCACTGAG 65 508 [21]
PKCα GGAACTCAGGCAGAAGTTCG CAGTTCCTCTGTTCCCTTCC 58 196 Original
IκBα GACGAGGATTACGAGCAGAT CCTGGTAGGTTACTCTGTTG 60 634 [22]
IκBβ CCCAAGAGATGCCTCAGATA GCCTTCATCTCTGTTGTCAC 65 520 [22]
NF-κB AAGATCAATGGCTACACGGG CCTCAATGTCTTCTTTCTGC 60 493 [23]
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTGGCTGTA 58 452 [24]
Table 2
Comparison of body weight, liver weight, and plasma glucose level
Group Body weight
(g)
Liver weight
(g)
Ratio of liver to body
weight (%)
Plasma glucose
(mg/dl)
Control 309±4.2 7.7±0.4 2.5±0.1 128±11
STZ 265±15⁎⁎ 8.1±0.6 3.0±0.1⁎⁎ 310±93⁎⁎
⁎⁎pb0.01 vs. control.
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rats with STZ-induced hyperglycemia. The results indicate that the
increased expression of Mdr1b P-gp is associatedwith the translocation
of the PKCα isoenzyme to membrane. Together with evidence for the
activation of NF-κB, we added a discussion about the system contribut-
ing to the up-regulation of Mdr1b P-gp in the diabetic rat liver.
2. Materials and methods
2.1. Animals
Male Wistar rats (9 weeks old, 280–300 g) were purchased from Japan SLC, Inc.
(Hamamatsu, Japan) and housed in a controlled environment. The rats were kept on a
commercial laboratory chow (CRF-1; Charles River Laboratories Japan, Inc., Yokohama,
Japan) and had free access to tap water. The STZ-induced diabetes was established with
a single intravenous injection of STZ (50 mg/kg body weight, Sigma) into the tail. The
control rats were injected with the vehicle (sodium citrate buffer, pH4.5). On the 7th
day after the injection, the increased urinary excretion of glucose was checked with a
commercial urine dipstick (Wako Pure Chemicals, Japan) and the next day the rats were
killed after starvation for 24 h. Blood was collected from the aorta abdominalis under
anesthesia with an intraperitoneal injection of pentobarbital (40 mg/kg) and the liver
was excised after perfusion with a 0.9% NaCl solution from the portal vein. Small pieces
of the liver were immersed into Trizol (Invitrogen Japan K.K.) for the isolation of total
RNA, and other parts of the tissue were frozen on dry ice and stored at −80 °C until
further use. All experiments were performed according to the institutional guidelines
for the care and use of laboratory animals in research.
2.2. Gene expression studies
Total RNA was isolated using Trizol reagent according to the manufacturer's
instructions. Then, cDNA was prepared by incubation of 0.5–1.0 µg of the RNA with
random primers (12.5 ng, Invitrogen), RNase inhibitor (RNaseOUT, 20 U, Invitrogen),
0.5 mM deoxynucleotides (dNTPs, Promega, WI), and 100 U of RNA reverse
transcriptase (ReverTra Ace, TOYOBO, Japan) in 20 µL of reaction buffer according to
the ReverTra Ace data sheet. Following inactivation of the enzyme by incubation at
99 °C for 5 min, polymerase chain reaction (PCR) was carried out with 0.625 U of G-Taq
Taq DNA polymerase (Hokkaido System Science Co., Japan) in 25 µL of PCR solution (1 µL
of cDNA solution, 0.4 µM primers, 0.2 mM dNTPs, and 2.5 µL of 10× PCR buffer) in a
Thermal Cycler PxE (Thermo Fisher Scientiﬁc, MA). PCR primers (Table 1) were
synthesized by Hokkaido System Science. The PCR products (10 µL) were electro-
phoresed on a 1.5% agarose gel and visualized with ultraviolet light after immersion in
an ethidium bromide solution (1 µg/mL) for 15 min. Images were taken with a digital
camera C-3030 zoom (Olympus, Japan) equipped with a BPB-60 ﬁlter (Fujiﬁlm Japan).
Densitometric analysis was performed using Scion Image for Windows supplied by the
Scion Corporation.
2.3. Western blot analysis of PKCα and P-gp
Small pieces of the liver were homogenized with a Potter–Elvehjem homogenizer
in 5 vol of Buffer A containing 10 mM Tris–HCl (pH7.5), 0.1 mM phenylmethylsulfonyl-
ﬂuoride (Sigma), and 1 mM dithiothreitol (Sigma). The homogenates were centrifuged
at 800 ×g for 10 min at 4 °C and then the supernatant was centrifuged at 15,000 ×g for
30 min at 4 °C. The 15,000 ×g supernatant was further centrifuged at 100,000 ×g for
30 min at 4 °C to obtain a cytosolic fraction (supernatant) and a microsomal fraction
(pellet). The pellet was re-suspended in a small volume of Buffer A. These fractionswere
used to detect PKC isoforms. The 15,000 ×g pellet was solubilized in Buffer A with 1%
Triton X100 and centrifuged at 15,000 ×g for 30 min at 4 °C. The resultant supernatant
(Fraction PM) was used for the detection of P-glycoprotein.The protein concentration was determined by using a DC protein assay kit (Bio-Rad
Laboratories, Inc.).
2.3.1. Detection of PKCα
The cytosolic and microsomal fractions were used for the detection of PKCα. Each
fraction (20–100 µg protein) was subjected to SDS-polyacrylamide gel electrophoresis
(SDS-PAGE, 10% gel), and the separated proteins were transferred onto an Immobilon-P
transfer membrane (Nihon Millipore, Japan). After blocking with skim milk, the
membrane was treated with an isoform-speciﬁc antibody for PKCα (Santa Cruz
Biotechnology, Inc., CA) followed by horseradish-labeled goat anti-mouse IgG1 antibody
(Santa Cruz Biotechnology, Inc.), and the speciﬁc immunoreactive band was detected
using an ECL-detection kit (Amersham Japan). Densitometric analysis was performed
using Scion Image for Windows.
2.3.2. Detection of P-gp
As was done for the detection of PKC isoforms, Fraction PM was isolated by SDS-
PAGE (8% gel) and then P-gp was detected with the C219 anti-MDR1 P-gp mouse
monoclonal antibody (Centocor, Inc., Malvern, PA) as a primary antibody and
horseradish-labeled goat anti-mouse IgG2a antibody (Santa Cruz Biotechnology, Inc.)
as a secondary antibody. The level of P-gp was detected and evaluated as described
above.
2.4. Western blot analysis of NF-κB p65
Cytoplasmic and nuclear fractions were prepared according to the report by Kiemer
et al. [20]. Each fraction (75–100 µg protein) was isolated by SDS-PAGE (10% gel), and
then NF-κB p65 was detected with anti-NF-κB p65 antibody (Cell Signaling Technology,
Inc., MA) as a primary antibody and horseradish-labeled goat anti-rabbit IgG antibody
(Cell Signaling Technology, Inc.) as a secondary antibody. The level of NF-κB p65 was
detected and evaluated as described above.
2.5. Statistical analysis
Data are shown as means±S.D. for ﬁve animals. Statistical analyses were performed
using Student's t-test.
3. Results
3.1. Phenotype of the control and STZ-induced diabetic rats
On the 8th day after the injection of STZ or vehicle, diabetic rats
had a signiﬁcantly lower body weight than the control rats (Table 2).
As the liver weight was not affected by the injection of STZ, the liver
weight/body weight ratio was signiﬁcantly increased. The average fast
blood glucose level of STZ-treated rats was 310 mg/dL compared to
Fig. 1. The expression levels of hepatic transporter genes in rats with STZ-induced
diabetes. The expression of transporter genes was investigated by semi-quantitative RT-
PCR methods using optimal concentrations of total RNA and primer sets shown in
Table 1. The photograph (A) is typical of each group. Column graph data are given
relative to the level of GAPDH and expressed as means±S.D. for ﬁve animals. ⁎Pb0.05,
compared with the control.
Fig. 2. The increase of hepatic P-gp levels in rats with STZ-induced diabetes. A liver
membrane fraction was subjected to a Western blot analysis of P-gp as described in
Materials and methods. Column graph data are means±S.D. for ﬁve animals. ⁎Pb0.05,
compared with the control. The photograph (A) is typical of each group.
Fig. 3. Expression and translocation of PKCα in the liver of rats with STZ-induced
diabetes. (A) The PKCαmRNAwas examined by semi-quantitative RT-PCR using optimal
concentrations of total RNA and primer sets shown in Table 1. (B) Western blot analysis
of PKCα. The microsomal and cytosolic fractions of the liver were prepared as described
in Materials and methods. The photograph is typical of each group. Column graph data
are means±S.D. for ﬁve animals. ⁎Pb0.05, compared with the control.
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animal model of diabetes.
3.2. Effects on hepatic drug transporters
As shown in Fig. 1(A, B), the semi-quantitative PCR-based analysis
of nine transporters revealed the upregulation (2-fold) of Mdr1b
mRNA expression in the liver of the diabetic rats. By contrast, Mdr1a
was not affected by the STZ-treatment as shown previously [10]. To
determine whether the increase in Mdr1b mRNA affects the P-gp
level, we conducted a Western blot analysis. As shown in Fig. 2, the
expression of P-gp was signiﬁcantly upregulated (2-fold) in the
diabetic rat liver. These results indicate that the increase in Mdr1b
mRNA level caused by STZ-treatment is large enough to raise the liver
concentration of P-gp. Although the mRNA levels of Mdr2, Mrp2, Bcrp,
Bsep, Oct1, Oat2, and Oat3 were investigated as shown in Fig. 1(A), no
detectable changes were observed. These results indicate that Mdr1b
is most sensitive to hyperglycemic conditions among these apical and
basolateral transporters in the liver.
3.3. Effects on PKC expression
PKC is a stimulating factor of P-gp expression [8,9] and is activated
in hyperglycemic conditions [13,14,21]. Moreover, PKCα and PKCβ2
isoforms have been indicated to be increased in STZ-induced diabetes
[22]. However, there are conﬂicting reports that PKCα levels were
lower in the hepatocytes of diabetic rats than normal rats [23] and that
the approximately 80 kDa PKCα was not increased in the cytosolic or
membrane fraction in the diabetic rats while the 90 kDa protein was[24]. Then, we investigated the mRNA and protein levels of PKCα as
shown in Fig. 3. The results showed that PKCα mRNA levels were not
affected in the STZ-induced diabetic model, while the Western blot
analysis revealed that the 80 kDa PKCα protein in the microsomal
fraction was signiﬁcantly increased while in the cytosolic fraction, the
PKCα protein level was not affected. These results indicated that the
production of PKCα protein was not induced and most of the protein
persistently translocated to the membrane in STZ-induced diabetes.
3.4. Effects on IκB and NF-κB expression
NF-κB, a major transcription factor of the MDR1 gene [25,26], has
been indicated to be persistently activated in diabetic state, and the
Fig. 4. Upregulation of the expression of IκB genes in the liver of rats with STZ-induced
diabetes. The expression of IκBα and IκBβ was examined by semi-quantitative RT-PCR
using optimal concentrations of total RNA and primer sets shown in Table 1. The
photograph (A) is typical of each group. Column graph data are given relative to the
level of GAPDH and expressed as means±S.D. for ﬁve animals. ⁎Pb0.05, ⁎⁎Pb0.01,
compared with the control.
Fig. 5.Upregulation of the expression of the NF-κB p65 gene in the liver of rats with STZ-
induced diabetes. The expression of the gene was examined by semi-quantitative RT-
PCR using optimal concentrations of total RNA and primer sets shown in Table 1. The
photograph (A) is typical of each group. Column graph data are given relative to the
level of GAPDH and expressed asmeans±S.D. for ﬁve animals. ⁎⁎Pb0.01, comparedwith
the control.
Fig. 6. Increase of nuclear NF-κB p65 in the liver of rats with STZ-induced diabetes. A
liver nuclear fractionwas subjected to aWestern blot analysis of NF-κB p65 as described
inMaterials andmethods. Column graph data aremeans±S.D. for ﬁve animals. ⁎Pb0.05,
compared with the control. The photograph (insert) is typical of each group.
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synthesis of NF-κB p65 in the presence of newly synthesized IκBα and
IκBβ [16]. Furthermore, it has been indicated that NF-κB was activated
by PKCα [27]. Then we investigated the mRNA levels of NF-κB p65,
IκBα and IκBβ in STZ-treated rats compared with the control rats. As
shown in Fig. 4, the NF-κB p65 mRNA level was increased by 50% and
IκBα and IκBβmRNA levels were increased 50% and 100% respectively
in the STZ-exposed rat liver. Next, the nuclear translocation of NF-κB
p65 was investigated by Western blotting. As shown in Fig. 5, we
detected increased nuclear translocation of p65 in STZ-treated rats
and a slight increase in cytoplasmic p65 levels.
4. Discussion
In the present study, we demonstrated an increase in P-gp among
nine hepatic canalicular and basolateral drug transporter genes
investigated, and the translocation of PKCα to the membrane and of
NF-κB p65 to the nucleus, in the liver of rats with STZ-induced
diabetes. Although P-gp is encoded by the Mdr1a and Mdr1b genes in
rats, only the Mdr1b gene expression was upregulated and con-
tributed to the increase in P-gp.
As for the level of P-gp under diabetic conditions, Tramonti et al.
[28] reported that, while the renal tubular Mdr1a and Mdr1b genes
were upregulated in their expression, P-gp levels were not affected in
diabetic rats. Contrary to this report, Liu et al. [29] showed that P-gp
levels in the brainwere lower in diabetic rodents than control animals.
Thus the present study clearly showed that the expression of liver P-gp
responded to the diabetic state in a different manner. Considering
that P-gp regulates the absorption, distribution, and disposition of a
large number of medicines and that hepatic P-gp confers vectorial
ﬂow of various lipophilic compounds into the canalicular space, the
increase in P-gp probably leads to the accelerated excretion of
medicines or xenobiotics into bile in the diabetic state.In the present study, concurrently with the upregulation of P-gp
expression in the liver, the level of PKCα in the membrane fraction
increased which generally means the activation of the enzyme. PKC-
related upregulation of MDR1 gene expression has been observed in
multidrug-resistant human tumor cells [8]. Generally, such resistant
cells express high levels of the PKCα isoform, and it has been shown
that PKCα contributed to the overexpression of P-gp [30,31].
Independently of P-gp research, isoform-speciﬁc increases in PKC
have been indicated by several studies in the rats with STZ-induced
diabetes Fig. 6. In renal and myocardial tissues, selective upregulation
of the expression of the PKCα isoform has been shown [32], and in
hepatocytes, increased levels of PKCα and -β2 isoforms and the
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ﬁndings, the present study is the ﬁrst to suggest an association of
PKCα with the upregulation of Mdr1b gene expression and P-gp level
in an animal model of diabetes.
VanWaarde et al. [6] reported that STZ-induced advanced diabetes
with high levels of serum bile acids induced Mdr2 gene expression in
the liver. However, we found no change of Mdr2 gene expression in
the present study. As the expression of the human MDR3 gene is
downregulated by PKCβ in vitro [33], and that of both the MDR3 and
Mdr2 genes can be upregulated by bile acids through the farnesoid X
receptor [34,35], we may have to consider the inﬂuence of these
factors and duration of disease on the expression of Mdr2 in models of
diabetes that use rats.
As for the persistent upregulation of PKC expression in diabetes, it
was indicated that it was generally accompanied by an increased
diacylglycerol (DAG) level and was caused by hyperglycemia [14]. On
the other hand, it is reported that hyperglycemia increased mitochon-
drial reactive oxygen species (ROS) production and also increased
ROS-mediated PKC activation [36]. As it has been shown that PKC
induced ROS production [37], PKC activation and ROS production may
mutually contribute to the sustained activation of PKC in the diabetic
state. Based on these reports, although further investigation is needed,
DAG and ROS production contribute to the induction of P-gp
expression and the increase in the level of PKCα in the membrane.
In the present study, we also indicated the activation of the
transcription factor NF-κB by showing upregulation of the transcrip-
tion and nuclear translocation of NF-κB p65 accompanied by increased
IκB transcription. It has been shown that phorbol ester, an activator of
PKC, induced the degradation of IκB and appearance of active NF-κB
(p65) [38]. Furthermore, it has been shown that PKCα induced the
activation of NF-κB [27] and that NF-κB is one of the major
transcription factors of the human MDR1 gene [25,39] and rat
Mdr1b gene [40]. Then, the activation of NF-κB in STZ-treated rats
seems to contribute to the transduction of PKCα activity to upregulate
the expression of P-gp.
IκB consists of IκBα and IκBβ subunits and forms a complex with NF-
κB (a heterodimerof p50 andp65) in the cytosol andplays amajor role in
the regulation of NF-κB activity. Degradation of IκBα after phosphoryla-
tion by IKK is followed by the translocation of NF-κB p65 and also by the
expression of IκB mRNA [41,42]. In calorie non-restricted aged rats,
increases in the mRNA and protein levels of IκBαwere found consistent
with the upregulated nuclear translocation of NF-κB p65 and in
correlation with age-related oxidative status [43,44]. These ﬁndings
imply that in chronic pathophysiological conditions both the nuclear
translocation of NF-κB and the expression of IκBα were persistently
upregulated. On the other hand, IκBβ binds to NF-κB in place of IκBα and
the complex translocates to the nucleus and it has been suggested that
this translocation contributed to the sustained activation of NF-κB
[45,46]. Considering the nuclear translocation of NF-κB p65 accompa-
niedby increased IκBβ transcription in thepresent STZ-generatedmodel
of diabetes, hyperglycemia seems to cause persistent activation of NF-κB
and to induce overexpression of hepatic P-gp.
In conclusion, we found a marked increase in the level of Mdr1b
P-gp in the liver at a relatively early stage of STZ-induced diabetes.
Thus we indicated that the distribution of xenobiotics is affected
through the upregulation of P-gp expression in the diabetic state.
Concomitantly with this upregulation, we also found activation of
the PKCα and NF-κB transcription system. From these ﬁndings, it is
strongly suggested that STZ-induced hyperglycemia caused the
upregulation of mdr1b P-gp expression through the activation of
PKCα and NF-κB.
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